AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01992198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutrition
Study NCT01992198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Study NCT01992198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Study NCT01992198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h
Study NCT00972985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: oral tablet, 100 mg, single acute dose
Study NCT00972985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: oral tablet, 20 mg, single acute dose
Study NCT00972985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorazepam
Description: oral tablet, 1 mg, single, acute dose
Study NCT00972985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet, single acute dose
Study NCT00989170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Program for the Prevention of Weight Gain
Description: The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
Study NCT04624633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral, twice a day, predetermined dosage
Study NCT04624633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
Study NCT04624633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: 28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
Study NCT01601392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (Anodal)
Description: The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
Study NCT01601392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (Cathodal)
Description: The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
Study NCT01601392 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (Sham)
Description: The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
Study NCT02659345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions Thermometer
Description: The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
Study NCT02659345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
Study NCT03229746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg twice daily orally for at least 12 weeks
Study NCT03229746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1mg intravenous weekly for 4 weeks
Study NCT03229746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: dose 100mg daily for at least 3 weeks
Study NCT01842893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Ethypharm
Description: After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
Study NCT00069953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
Study NCT00069953 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: External beam radiotherapy with megavoltage linear accelerators (> 6 MV) will be used to deliver multiple (> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
Study NCT01063881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
Study NCT01309100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens
Description: Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
Study NCT01309100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Lens
Description: Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
Study NCT01309100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua Lens
Description: Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
Study NCT00197873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus supplementation
Description: Lactophilus supplementation is administered during chemotherapy.
Study NCT00197873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Rhamnosus supplementation
Description: Lactophilus supplementation is administered during chemotherapy.
Study NCT00197873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration.
Description: Placebo is administered during chemotherapy.
Study NCT02452619 — intervention group
Intervention type: OTHER
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy
Study NCT02290262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive phase one rehabilitation
Description: Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse.
Study NCT02663349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Intervention Training
Description: A manualized group therapy that teaches social cognitive skills.
Study NCT02923336 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: non selective beta blocker
Description: the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time
Study NCT02096705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet
Study NCT02096705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin Placebo
Description: Tablet
Study NCT03669731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food diary
Description: This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
Study NCT01328782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone with Acetaminophen
Description: 0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
Study NCT01328782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: * Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg
Study NCT01328782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.20%
Description: * Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg
Study NCT04224584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
Study NCT04224584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will act as a control for duloxetine.
Study NCT03946436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active video games
Description: Participants played the active video game Virtua tennis 4 on a playstation kinect device
Study NCT03946436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tennis training process
Description: Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
Study NCT03946436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tennis training process
Description: Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
Study NCT04124354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
Study NCT02230267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise and balance training
Study NCT02230267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care arm exercise
Study NCT02011828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: 50,000 IU/week
Study NCT02011828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study NCT04541173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Y-90 TARE
Description: This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres.
Study NCT04541173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-90 TARE
Description: This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres.
Study NCT04541173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
Study NCT04541173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
Study NCT00695045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 100 mcg intrathecal morphine given once .
Study NCT00695045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 200 mcg intrathecal morphine given once
Study NCT00695045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 300 mcg intrathecal morphine given once
Study NCT00845130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ascorbic acid (Vitamin C)
Description: ascorbic acid IV 1 g/kg
Study NCT01143337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-435(dose1) + Methotrexate
Description: MP-435 dose1 + stable weekly dose of Methotrexate
Study NCT01143337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate
Description: Placebo + stable weekly dose of Methotrexate
Study NCT03086434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Intervention
Description: School-based substance use prevention
Study NCT03086434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Substance Abuse Education
Description: Class room program
Study NCT00989170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
Study NCT03160911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC)
Description: The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
Study NCT03160911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Endoscopic Haemostasis
Description: This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
Study NCT00651469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
Study NCT00651469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Study NCT04125017 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with laser pulse
Description: Using laser pulse before ICSI
Study NCT04125017 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with micro needle technique
Description: Using micro needle technique before ICSI
Study NCT03883685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotane
Description: probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
Study NCT04777552 — intervention group
Intervention type: OTHER
Intervention: diazepam (or equivalence if other benzodiazepine)
Study NCT01683773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intradermal needle injection 1x10\^8 pfu
Study NCT01650155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1005273 s.c.
Description: injection
Study NCT01650155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 105273 i.v. Placebo
Description: infusion
Study NCT01650155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 1005273 s.c. Placebo
Description: injection
Study NCT01650155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1005273 i.v.
Description: infusion
Study NCT04738968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
Study NCT03276767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre
Description: The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt.
Study NCT03276767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endre
Description: The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt.
Study NCT03883685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03492996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose
Description: To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
Study NCT04333264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suction drainage
Description: After primary total hip arthroplasty closed suction drainage will be used.
Study NCT04333264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suction drainage
Description: After primary total hip arthroplasty closed suction drainage won't be used.
Study NCT01723683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant
Study NCT01723683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Study NCT03258957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Milk
Description: Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk